Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting—Practice and Outcomes

There has been an alarming rise in the incidence of esophageal adenocarcinoma which continues to have poor survival rates primarily due to lack of effective chemotherapy and presentation at advanced stages. Over a dozen chemotherapeutic agents are FDA approved for esophageal cancer (EC), and a two o...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdo, Joe, Bertellotti, Carrie A., Cornell, David L., Agrawal, Devendra K., Mittal, Sumeet K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513914/
https://www.ncbi.nlm.nih.gov/pubmed/28770168
http://dx.doi.org/10.3389/fonc.2017.00151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513914/
https://www.ncbi.nlm.nih.gov/pubmed/28770168
http://dx.doi.org/10.3389/fonc.2017.00151

Ejemplares similares